Group 1 - The first prescription for China's first approved stem cell drug, Amy Maitosai Injection, has been issued, marking its official market entry and providing new treatment options for patients [1][2] - The drug is priced at 19,800 yuan per treatment, which is only 1/70th of a similar stem cell drug recently approved by the FDA in the United States [1] - The drug is indicated for treating acute graft-versus-host disease in patients aged 14 and above who have failed hormone therapy, addressing a significant treatment gap for these patients [2] Group 2 - ZhongAn Insurance, as a strategic partner of PlasBio, offers coverage for the drug under its health insurance products, with a maximum reimbursement rate of 100% for eligible patients, alleviating their financial burden [2] - The company has been adapting its health insurance products to align with advancements in medical treatments and the ongoing reform of medical insurance payment methods, enhancing its competitiveness in the market [3] - Since 2025, ZhongAn Insurance has expanded its coverage to include external purchased drugs and medical devices in its health insurance offerings, addressing the limitations of traditional medical insurance [3] Group 3 - ZhongAn Insurance has implemented various innovative attempts in the medical insurance sector this year, including enhanced outpatient coverage and the development of exclusive insurance products for patients with pre-existing conditions [3] - The company aims to create a "health insurance + health management" model through comprehensive health management services, thereby improving product competitiveness [3] - ZhongAn Insurance expresses its intention to deepen collaboration with PlasBio to explore and promote inclusive insurance services that meet diverse healthcare needs [4]

Core Viewpoint - The issuance of the first prescription for mesenchymal stem cell drugs marks a significant breakthrough in the clinical application of stem cell therapies in China, transitioning from research achievements to accessible treatments [1]. Group 1: Clinical Application of Stem Cell Therapy - On June 5, 2025, the first prescription for a marketed mesenchymal stem cell drug was issued by a team led by Academician Huang Xiaojun at Peking University People's Hospital for a patient undergoing haploidentical transplantation [1]. - The first stem cell therapy drug, Aimi Maito Sai injection (Ruibo Sheng), received conditional approval from NMPA on January 2, 2025, targeting acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic stem cell transplantation [1]. - This innovative therapy utilizes human umbilical mesenchymal stem cells to regulate T-cell overactivation and inflammatory cytokine storms, providing a new solution for life-threatening immune attacks affecting multiple organs [1]. Group 2: Development of Health Industry in Jiangxi - Jiangxi's Ganjiang New Area is focusing on the life and health industry, aiming to enhance the industrial chain by integrating research and application, forming a cluster that includes traditional Chinese medicine, medical devices, beauty health products, and biomedicine [1]. - Antu Bio, a leading company in the in vitro diagnostics field, is collaborating with the Ganjiang New Area to leverage its strong research capabilities and advanced core technologies to maintain its leading position in the industry [1]. - The partnership aims to promote the deep integration of innovation chains, industrial chains, financial chains, and talent chains, establishing a modern industrial system with distinctive advantages [1]. Group 3: Strategic Positioning of Ganjiang New Area - Ganjiang New Area is recognized as a national-level new area, serving as a comprehensive functional platform with unique policy integration advantages and a conducive industrial development environment [2]. - The area is positioned to become a "bridgehead" and frontier for the high-end development of the in vitro diagnostics industry in Jiangxi Province [2]. - The collaboration with Antu Bio is expected to initiate high-standard and efficient development in artificial intelligence and smart testing systems [3].